Literature DB >> 15795555

Psychotropic drug interactions with valproate.

Jessica Fleming1, Manoranjenni Chetty.   

Abstract

Valproate is a well-established anticonvulsant that is increasingly being employed, often in combination with other psychotropics, for its mood-stabilizing properties. This compound is metabolized by conjugation, beta-oxidation, and cytochrome P450 oxidation (CYP2C9, CYP2C19, and CYP2A6) and also acts as a broad-spectrum inhibitor of a variety of hepatic enzymes including glucoronyltransferase, epoxide hydrolase, and the CYP2C enzymes. In addition, it exhibits saturable protein binding and competes with many drugs for protein binding sites. It is therefore not surprising that valproate has been noted to interact with psychotropic medications of all classes. This article provides an overview of the noted pharmacokinetic psychotropic interactions with valproate, with a particular focus on the mechanisms of these interactions and potential clinical consequences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795555     DOI: 10.1097/01.wnf.0000154221.37887.73

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report.

Authors:  Benedict Morath; K Green; M Zaradzki; J Heid; M Karck; T Hoppe-Tichy
Journal:  Eur J Clin Pharmacol       Date:  2018-01-23       Impact factor: 2.953

2.  Infusion of Valproic Acid Into the Renal Medulla Activates Stem Cell Population and Attenuates Salt-Sensitive Hypertension in Dahl S Rats.

Authors:  Zhengchao Wang; Qing Zhu; Weili Wang; Fan Yi; Pin-Lan Li; Krishna M Boini; Ningjun Li
Journal:  Cell Physiol Biochem       Date:  2017-07-11

3.  Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.

Authors:  Anita Rakic Ignjatovic; Branislava Miljkovic; Dejan Todorovic; Ivana Timotijevic; Milena Pokrajac
Journal:  Br J Clin Pharmacol       Date:  2008-12-05       Impact factor: 4.335

4.  Three patients needing high doses of valproic Acid to get therapeutic concentrations.

Authors:  James Jackson; Betsy McCollum; Judy Ognibene; Francisco J Diaz; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2015-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.